HomeCompareXVIPF vs NOBL

XVIPF vs NOBL: Dividend Comparison 2026

XVIPF yields 8.77% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 XVIPF wins by $12.9K in total portfolio value
10 years
XVIPF
XVIPF
● Live price
8.77%
Share price
$22.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.7K
Annual income
$1,524.79
Full XVIPF calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — XVIPF vs NOBL

📍 XVIPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXVIPFNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XVIPF + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XVIPF pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XVIPF
Annual income on $10K today (after 15% tax)
$745.26/yr
After 10yr DRIP, annual income (after tax)
$1,296.07/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, XVIPF beats the other by $1,086.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XVIPF + NOBL for your $10,000?

XVIPF: 50%NOBL: 50%
100% NOBL50/50100% XVIPF
Portfolio after 10yr
$29.3K
Annual income
$885.49/yr
Blended yield
3.02%
📊

Analyst Conviction Gap

Where Wall Street is split right now

XVIPF
Analyst Ratings
1
Buy
1
Sell
Consensus: Buy
Altman Z
16.5
Piotroski
5/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XVIPF buys
0
NOBL buys
0
No recent congressional trades found for XVIPF or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXVIPFNOBL
Forward yield8.77%2.14%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$35.7K$22.8K
Annual income after 10y$1,524.79$246.19
Total dividends collected$12.0K$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: XVIPF vs NOBL ($10,000, DRIP)

YearXVIPF PortfolioXVIPF Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$11,577$876.78$10,914$214.34+$663.00XVIPF
2$13,336$948.62$11,897$218.63+$1.4KXVIPF
3$15,291$1,021.27$12,952$222.72+$2.3KXVIPF
4$17,455$1,094.36$14,086$226.62+$3.4KXVIPF
5$19,845$1,167.56$15,302$230.33+$4.5KXVIPF
6$22,474$1,240.55$16,607$233.85+$5.9KXVIPF
7$25,361$1,313.03$18,007$237.18+$7.4KXVIPF
8$28,521$1,384.72$19,508$240.35+$9.0KXVIPF
9$31,972$1,455.38$21,116$243.35+$10.9KXVIPF
10$35,735$1,524.79$22,841$246.19+$12.9KXVIPF

XVIPF vs NOBL: Complete Analysis 2026

XVIPFStock

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

Full XVIPF Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this XVIPF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XVIPF vs SCHDXVIPF vs JEPIXVIPF vs OXVIPF vs KOXVIPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.